PopVax Announces 1.15 Million USD in Funding from the Bill and Melinda Gates Foundation for Thermostable mRNA Delivery Formulation Development
BusinessWire India Mumbai Maharashtra Hyderabad Telangana [India] October 30 PopVax an Indian full-stack biotechnology ...
Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments
Lexaria's strategy is to continue developing and optimizing our wholly-owned DehydraTECH™ drug delivery platform for application in the GLP-1 space, positioning it as a 'must-have' technology for ...
PMLiVE5d
Novo Nordisk and Ascendis enter $285m partnership for once-monthly GLP-1 drug
The companies will use Ascendis’ TransCon technology to develop therapies for metabolic and cardiovascular diseases ...
PMLiVE9d
Novo Nordisk’s GLP-1 drug semaglutide shows promise in fatty liver disease MASH
The reesults come less than two months after Novo entered into a multi-year partnership worth $600m with NanoVation Therapeutics to advance genetic medicines for cardiometabolic and rare diseases. The ...
Business Wire14d
PopVax Announces 1.15 Million USD in Funding from the Bill & Melinda Gates Foundation for Thermostable mRNA Delivery Formulation Development
who previously worked with pioneering nucleic acid delivery research groups at NanoVation Therapeutics and during his PhD at the University of British Columbia in Canada. “We at PopVax are ...
TheStreet.com13d
Nanovation Microtech Inc
Google parent Alphabet overcame a key investor concern as it posted stronger-than-expected third quarter earnings.
emjreviews.com22d
Transforming Care in SEA: Evidence and Considerations for Evolution of the Current Treatment Paradigm
Nanovation Therapeutics, Olympus Medical, Pulmonx, Roche Diagnostics, and Uptake Medical. Korn has received research support from AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici, GSK, Novartis, ...